ENTEROMEDICS INC. (NASDAQ:ETRM) Files An 8-K Other Events

Item8.01 Other Events.

On January23, 2017, EnteroMedics Inc. (the Company) issued a
press release announcing the closing of its previously announced
underwritten public offering of (i)751,412 shares of the Companys
common stock, par value $0.01 (the Common Stock), (ii)3,111,299
Common Stock Purchase Warrants (Warrants), (iii)12,531 Shares of
Series A Convertible Preferred Stock, (iv)466,695 shares of
Common Stock to exercise of the overallotment option, and
(v)466,695 Warrants to exercise of the overallotment option. The
Company received gross proceeds of $19.0 million, which includes
the full exercise of the underwriters over-allotment option to
purchase additional shares of Common Stock and Warrants, prior to
deducting underwriting discounts and commissions and offering
expenses payable by the Company.

A copy of the press release is included as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.

to the closing of the Offering, the Company entered into a
warrant agency agreement (the Warrant Agency Agreement) with
Wells Fargo Bank, National Association (Wells Fargo) on
January20, 2017, to which Wells Fargo will serve as the Companys
Warrant Agent for the Offering. The Warrant Agency Agreement is
included as Exhibit 10.1 to this Current Report on Form 8-K and
incorporated herein by reference.

Further information on the terms of the Offering can be found on
the Companys Registration Statement on Form S-1 (File
No.333-213704), which was declared effective by the United States
Securities and Exchange Commission on January17, 2017.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits

About ENTEROMEDICS INC. (NASDAQ:ETRM)

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

ENTEROMEDICS INC. (NASDAQ:ETRM) Recent Trading Information

ENTEROMEDICS INC. (NASDAQ:ETRM) closed its last trading session down -0.49 at 6.98 with 3,197,394 shares trading hands.